Zydus Lifesciences Limited has announced the resignation of Dr. Amrut Naik as President and Business Unit Head, International Markets Business, effective October 31, 2026. Following the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Mr. Christoph Stoller to the same position. Mr. Stoller will assume his new role, becoming part of the Senior Management team, with his appointment date set for November 2, 2026.
Senior Management Transition at Zydus Lifesciences
Zydus Lifesciences Limited has made a significant announcement regarding a change in its senior management. Dr. Amrut Naik has tendered his resignation from the position of President and Business Unit Head, International Markets Business. His resignation was effective October 31, 2026, and he will be relieved of his duties on November 7, 2026. This transition marks his cessation from the Senior Management team of the company.
New Leadership for International Markets
In light of Dr. Naik’s departure, the Board of Directors, acting upon the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Mr. Christoph Stoller as the new President and Business Unit Head for the International Markets Business. Mr. Stoller’s appointment signifies a new chapter for the company’s international operations, and he will officially become a part of the Senior Management team. His date of appointment is set for November 2, 2026, with the term of his employment being full-time.
About Mr. Christoph Stoller
Mr. Christoph Stoller brings over 30 years of global experience in the pharmaceutical industry. He is a seasoned leader with a background in branded pharmaceuticals, specialty medicines, and innovative therapies. His career includes significant leadership roles such as CEO and President across various international markets, including Europe, Emerging Markets, LATAM, and APAC. He holds a degree in Business Administration, Economics, Law, and Social Sciences from the University of St. Gallen, Switzerland.
Previously, Mr. Stoller served as President & Business Head (EMEA, LATAM & APAC) at Glenmark Pharmaceuticals, where he led a large team and managed a P&L exceeding USD 750 million. His major career highlights include doubling European revenue at Glenmark and leading commercialization efforts for innovative products. He also held senior positions at Teva Pharmaceuticals for a decade, managing extensive operations in Europe. His experience also extends to leadership roles at Helvepharm AG and Zur Rose Group, where he successfully transformed businesses.
Source: BSE
